A $300 million settlement has been reached in the multidistrict Benicar litigation against Daiichi Sankyo Inc. and Forest Laboratories Inc. on claims that the top-selling blood pressure drug caused severe, and sometimes life-threatening, gastrointestinal injuries in users. [Read more…]
Benicar is a widely prescribed medication for blood pressure and hypertension (chronic high blood pressure). Olmesartan is the active ingredient of Benicar and is also contained in Benicar HCT, Tribenzor, and Azor.
Lieff Cabraser attorney Lexi J. Hazam is speaking at HarrisMartin’s MDL Conference: Zofran, Bard IVC and Zimmer Persona Knee Litigation on July 29, 2015 at Hotel Nikko in San Francisco. Hazam will be featured as a panelist discussing the Benicar (Olmesartan) Litigation. Hazam has been appointed by the court overseeing the nationwide Benicar MDL litigation to the Plaintiffs’ Steering Committee, and serves as Co-Chair of the MDL Plaintiffs’ Science and Experts Committee.
Lieff Cabraser attorney Lexi J. Hazam announced that three patients prescribed olmesartan, a widely-prescribed blood pressure medication sold under the brand name Benicar, along with Benicar HT, Tribenzor and Azor, recently filed lawsuits against Japan-based Daiichi Sankyo, Benicar’s manufacturer, and Forest Laboratories, which marketed and distributed Benicar in the United States.
The U.S. Food and Drug Administration has warned that patients with high blood pressure taking Benicar could suffer serious side effects including chronic diarrhea, unusual weight loss, and severe gastrointestinal problems.
Lieff Cabraser attorney Lexi J. Hazam will be discussing the Benicar prescription drug litigation at the 15th Anniversary of the Mass Torts Made Perfect Seminar on April 17, 2015 in Las Vegas, Nevada. Attorneys from across the nation attend the annual conference to learn from leaders of the plaintiffs’ bar of the latest developments in lawsuits involving defective and dangerous prescription drugs, medical devices, and other products that collectively have injured tens of thousands of Americans.
Attorney Lexi Hazam of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that two patients prescribed olmesartan medoxomil, a widely-prescribed medication sold under the brand name Benicar, today filed a personal injury lawsuit alleging that Benicar is a dangerous and defective drug. The complaint, filed in federal court in San Francisco, names as defendants Japanese-based Daiichi Sankyo, Benicar’s manufacturer, and Forest Laboratories, which marketed Benicar in the U.S. Steven W. Teppler of the Abbott Law Group, P.A. from Jacksonville, Florida, also serves as counsel for plaintiffs. [Read more…]